Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients

The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Mohamed A., Sorio, Claudio, Al-Dewik, Nader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Commentary & View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677154/
https://www.ncbi.nlm.nih.gov/pubmed/36382578
http://dx.doi.org/10.1177/10732748221140201
Descripción
Sumario:The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patients due to TKIs, still over 25% of CML patients need to switch TKIs at least once during treatment timeline for many reasons. On the other hand, PTPRG behave as a tumor suppressor gene in different neoplasms and is strongly down-regulated in CML patients. We discussed briefly in series of articles the possible reasons of it is down regulation. Here, we discuss its role as potential therapeutic target in treatment plan.

Ejemplares similares